1. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
- Author
-
Afifi Salma, Foss Francine, Zhao Jennifer C, and Jaszczur Sara Mohamed
- Subjects
Refractory Peripheral T-cell Lymphoma ,business.industry ,T cell ,Lymphoproliferative disorders ,Pralatrexate ,Lymphoma, T-Cell, Peripheral ,Hematology ,medicine.disease ,Peripheral T-cell lymphoma ,Peripheral ,Aminopterin ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,medicine ,Conventional chemotherapy ,Humans ,Pralatrexate Injection ,business ,030215 immunology ,medicine.drug - Abstract
Peripheral T cell lymphomas (PTCL) are a heterogenous group of lymphoproliferative disorders which are generally not curable with conventional chemotherapy and associated with inferior outcomes. Pralatrexate is a novel folate analog, the first FDA approved drug) for the treatment of relapsed/refractory (R/R) PTCL.This paper provides a comprehensive review of PubMed literature describing the use of pralatrexate in R/R peripheral T-cell lymphoma. Pharmacokinetics and mechanism of action of pralatrexate are discussed as well as its clinical efficacy and safety in comparison to other agents available in R/R PTCL.Pralatrexate is an active agent in relapsed/refractory PTCL with lower response rates seen in patients with angioimmunoblastic T cell lymphomas. Mucositis is the most frequently observed adverse event and this can be mitigated by the use of leucovorin along with cyanocobalamin and folic acid.
- Published
- 2020